Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DCSpecial Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)PLUS Meeting Abstract SummariesWith Expert Commentary by:Fred Poordad, MDChief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.

Literature DB >> 29950953

A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DCSpecial Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)PLUS Meeting Abstract SummariesWith Expert Commentary by:Fred Poordad, MDChief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.

Abstract

Entities: Disease Gene Species

Year: 2017 PMID： 29950953 PMCID： PMC6015237

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

14 in total

1. EASL Recommendations on Treatment of Hepatitis C 2016.

Authors:
Journal: J Hepatol Date: 2016-09-22 Impact factor: 25.083

2. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Authors: Xavier Forns; Samuel S Lee; Joaquin Valdes; Sabela Lens; Reem Ghalib; Humberto Aguilar; Franco Felizarta; Tarek Hassanein; Holger Hinrichsen; Diego Rincon; Rosa Morillas; Stefan Zeuzem; Yves Horsmans; David R Nelson; Yao Yu; Preethi Krishnan; Chih-Wei Lin; Jens J Kort; Federico J Mensa
Journal: Lancet Infect Dis Date: 2017-08-14 Impact factor: 25.071

3. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

Authors: Katja Deterding; Christoph D Spinner; Eckart Schott; Tania M Welzel; Guido Gerken; Hartwig Klinker; Ulrich Spengler; Johannes Wiegand; Julian Schulze Zur Wiesch; Anita Pathil; Markus Cornberg; Andreas Umgelter; Caroline Zöllner; Stefan Zeuzem; Armin Papkalla; Kristina Weber; Svenja Hardtke; Heiko von der Leyen; Armin Koch; Dorothee von Witzendorff; Michael P Manns; Heiner Wedemeyer
Journal: Lancet Infect Dis Date: 2016-10-28 Impact factor: 25.071

4. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.

Authors: Jürgen K Rockstroh; Sanjay Bhagani; Robert H Hyland; Chohee Yun; Hadas Dvory-Sobol; Wei Zheng; Diana M Brainard; Patrick Ingiliz; Thomas Lutz; Christoph Boesecke; Mark Nelson
Journal: Lancet Gastroenterol Hepatol Date: 2017-03-01

5. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Authors: Stefan Zeuzem; Reem Ghalib; K Rajender Reddy; Paul J Pockros; Ziv Ben Ari; Yue Zhao; Deborah D Brown; Shuyan Wan; Mark J DiNubile; Bach-Yen Nguyen; Michael N Robertson; Janice Wahl; Eliav Barr; Joan R Butterton
Journal: Ann Intern Med Date: 2015-07-07 Impact factor: 51.598

6. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Authors: Jürgen K Rockstroh; Mark Nelson; Christine Katlama; Jay Lalezari; Josep Mallolas; Mark Bloch; Gail V Matthews; Michael S Saag; Philippe J Zamor; Chloe Orkin; Jacqueline Gress; Stephanie Klopfer; Melissa Shaughnessy; Janice Wahl; Bach-Yen T Nguyen; Eliav Barr; Heather L Platt; Michael N Robertson; Mark Sulkowski
Journal: Lancet HIV Date: 2015-07-09 Impact factor: 16.070

7. Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.

Authors: Christophe Hézode; Massimo Colombo; Marc Bourlière; Ulrich Spengler; Ziv Ben-Ari; Simone I Strasser; William M Lee; Leslie Morgan; Jingjun Qiu; Peggy Hwang; Michael Robertson; Bach-Yen Nguyen; Eliav Barr; Janice Wahl; Barbara Haber; Robert Chase; Rohit Talwani; Vito Di Marco
Journal: Hepatology Date: 2017-07-20 Impact factor: 17.298

8. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Authors: Paul Kwo; Edward J Gane; Cheng-Yuan Peng; Brian Pearlman; John M Vierling; Lawrence Serfaty; Maria Buti; Stephen Shafran; Paul Stryszak; Li Lin; Jacqueline Gress; Stuart Black; Frank J Dutko; Michael Robertson; Janice Wahl; Lisa Lupinacci; Eliav Barr; Barbara Haber
Journal: Gastroenterology Date: 2016-10-05 Impact factor: 33.883

9. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

Authors: Craig A Coburn; Peter T Meinke; Wei Chang; Christine M Fandozzi; Donald J Graham; Bin Hu; Qian Huang; Stacia Kargman; Joseph Kozlowski; Rong Liu; John A McCauley; Amin A Nomeir; Richard M Soll; Joseph P Vacca; Dahai Wang; Hao Wu; Bin Zhong; David B Olsen; Steven W Ludmerer
Journal: ChemMedChem Date: 2013-10-14 Impact factor: 3.540

10. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Authors: Marc Bourlière; Stuart C Gordon; Steven L Flamm; Curtis L Cooper; Alnoor Ramji; Myron Tong; Natarajan Ravendhran; John M Vierling; Tram T Tran; Stephen Pianko; Meena B Bansal; Victor de Lédinghen; Robert H Hyland; Luisa M Stamm; Hadas Dvory-Sobol; Evguenia Svarovskaia; Jie Zhang; K C Huang; G Mani Subramanian; Diana M Brainard; John G McHutchison; Elizabeth C Verna; Peter Buggisch; Charles S Landis; Ziad H Younes; Michael P Curry; Simone I Strasser; Eugene R Schiff; K Rajender Reddy; Michael P Manns; Kris V Kowdley; Stefan Zeuzem
Journal: N Engl J Med Date: 2017-06-01 Impact factor: 91.245

12 in total

1. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder.

Authors: Sandra A Springer
Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079

2. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients.

Authors: David Chromy; Mattias Mandorfer; Theresa Bucsics; Philipp Schwabl; Bernhard Scheiner; Caroline Schmidbauer; Maximilian Christopher Aichelburg; Peter Ferenci; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger
Journal: United European Gastroenterol J Date: 2019-03-06 Impact factor: 4.623

3. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.

Authors: Matthew J Akiyama; Daniel Lipsey; Moonseong Heo; Linda Agyemang; Brianna L Norton; Jennifer Hidalgo; Kiara Lora; Alain H Litwin
Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079

4. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.

Authors: Peng Huang; Yan Wang; Ming Yue; Zhijun Ge; Xueshan Xia; Andre J Jeyarajan; Jacinta A Holmes; Rongbin Yu; Chuanwu Zhu; Sheng Yang; Wenyu Lin; Raymond T Chung
Journal: Liver Int Date: 2021-06-16 Impact factor: 8.754

5. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.

Authors: Jürgen K Rockstroh; Karine Lacombe; Rolando M Viani; Chloe Orkin; David Wyles; Anne F Luetkemeyer; Ruth Soto-Malave; Robert Flisiak; Sanjay Bhagani; Kenneth E Sherman; Tatiana Shimonova; Peter Ruane; Joseph Sasadeusz; Jihad Slim; Zhenzhen Zhang; Suvajit Samanta; Teresa I Ng; Abhishek Gulati; Matthew P Kosloski; Nancy S Shulman; Roger Trinh; Mark Sulkowski
Journal: Clin Infect Dis Date: 2018-09-14 Impact factor: 9.079

6. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.

Authors: Robert J Fontana; Sabela Lens; Stuart McPherson; Magdy Elkhashab; Victor Ankoma-Sey; Mark Bondin; Ana Gabriela Pires Dos Santos; Zhenyi Xue; Roger Trinh; Ariel Porcalla; Stefan Zeuzem
Journal: Adv Ther Date: 2019-10-23 Impact factor: 3.845

7. A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis.

Authors: Jae Hyun Yoon; Sun Min Kim; Gaeun Kang; Hee Joon Kim; Chung Hwan Jun; Sung Kyu Choi
Journal: Medicine (Baltimore) Date: 2019-09 Impact factor: 1.817

8. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.

Authors: Ashley Brown; Tania M Welzel; Brian Conway; Francesco Negro; Norbert Bräu; Jason Grebely; Massimo Puoti; Alessio Aghemo; Henning Kleine; David Pugatch; Federico J Mensa; Yaozhu J Chen; Yang Lei; Eric Lawitz; Tarik Asselah
Journal: Liver Int Date: 2019-10-18 Impact factor: 5.828

9. Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men.

Authors: Paari M Palaniswami; Ahmed El Sayed; Benjamin Asriel; Jesse R Carollo; Daniel S Fierer
Journal: Open Forum Infect Dis Date: 2018-09-21 Impact factor: 3.835

10. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting.

Authors: Arshia Alimohammadi; Julie Holeksa; Astou Thiam; David Truong; Brian Conway
Journal: Open Forum Infect Dis Date: 2018-05-23 Impact factor: 3.835